Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry

NeuroImage

Volumn 54, Issue 2, 2011, Pages 794-801

  Daumann, Jörg ^a   Koester, Philip ^a   Becker, Benjamin ^a   Wagner, Daniel ^a   Imperati, Davide ^b   Gouzoulis Mayfrank, Euphrosyne ^a   Tittgemeyer, Marc ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Amphetamines; Gray matter; Morphometry; Stimulants; Tract based spatial statistics

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CENTRAL STIMULANT AGENT;

ADULT; ANISOTROPY; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG DEPENDENCE; FEMALE; FRONTAL CORTEX; GRAY MATTER; GRAY MATTER SIZE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AMPHETAMINE; AMPHETAMINES; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PREFRONTAL CORTEX; STREET DRUGS;

EID: 78649663178     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.08.065     Document Type: Article

References (71)

1. Andersson J.L.R., Jenkinson M., Smith S. Non-linear optimization. FMRIB Technical Report 2007, Available at http://www.fmrib.ox.ac.uk/analysis/techrep/tr07ja1/tr07ja1.pdf. Accessed August 4, 2009.
2. Andersson J.L.R., Jenkinson M., Smith S. Non-linear registration, aka spatial normalization. FMRIB Technical Report 2007, Available at http://www.fmrib.ox.ac.uk/analysis/techrep/tr07ja2/tr07ja2.pdf. Accessed August 4, 2009.
3. Aron J.L., Paulus M.P. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction 2007, 102:33-43.
4. Ashburner J., Friston K. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
5. Bartzokis G., Beckson M., Lu P.H., Edwards N., Rapoport R., Wiseman E., Bridge P. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatry Res. 2000, 98:93-102.
6. Berman S., O'Neill J., Fears S., Bartzokis G., London E.D. Abuse of amphetamines and structural abnormalities in the brain. Ann. N. Y. Acad. Sci. 2008, 1141:195-220.
7. Boutrel B., Koob G.F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004, 27:1181-1194.
8. Brody A.L., Mandelkern M.A., Jarvik M.E., Lee G.S., Smith E.C., Huang J.C., Bota R.B., Bartzokis G., London E.D. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol. Psychiatry 2004, 55:77-84.
9. Cowan R.L., Lyoo I.K., Sung S.M., Ahn K.H., Kim M.J., Hwang J., Vimal R.L.P., Lukas S.E., Renshaw P.F. Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend. 2003, 72:225-235.
10. Daumann J., Pelz S., Becker S., Tuchtenhagen F., Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum. Psychopharmacol. 2001, 16:627-633.
11. Daumann J., Fischermann T., Heekeren K., Thron A., Gouzoulis-Mayfrank E. Neural mechanisms of working memory in ecstasy users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol. Psychiatry 2004, 56:349-355.
12. De La Garza R., Fabrizio K.R., Gupta A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology 2007, 189:425-434.
13. De Win M.M.L., Reneman L., Jager G., Vlieger E.J.P., Olabarriaga S.D., Lavini C., Bisschops I., Majoie C.B.L.M., Booij J., den Heeten G.J., van den Brink W. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropharmacology 2007, 32:458-470.
14. Easton N., Marsden C.A. Ecstasy: are animal data consistent between species and can they translate to humans?. J. Pharmacol. 2006, 20:194-210.
15. Elliott R., Dolan R.J., Frith C.D. Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. Cereb. Cortex 2000, 10:308-317.
16. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. Annual report: the state of the drugs problem in Europe, 2008. Available at Accessed October 12, 2009. http://www.emcdda.europa.eu/publications/annual-report/2008.
17. Ersche K.D., Fletcher P.C., Lewis S.J.G., Clark L., Stocks-Gee G., London M., Deakin J.B., Robbins T.W., Sahakian B.J. Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology (Berl) 2005, 180:612-623.
18. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+?)-3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J. Neurosci. 1995, 15:5467-5485.
19. Gallinat J., Meisenzahl E., Jacobsen L.K., Kalus P., Bierbauer J., Kienast T., Witthaus H., Leopold K., Seifert F., Schubert F., Staedtgen M. Smoking and structural brain deficits: a volumetric MR investigation. Eur. J. Neurosci. 2006, 24:1744-1750.
20. Good C., Johnsrude I., Ashburner J., Henson R., Friston K., Frackowiak R. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
21. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 2006, 101:348-361.
22. Gouzoulis-Mayfrank E., Becker S., Pelz S., Tuchtenhagen F., Daumann J. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?. Biol. Psychiatry 2002, 51:766-769.
23. Grant S., Contoreggi C., London E.D. Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia 2000, 38:1180-1187.
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
25. Hall D.A., Stanis J.J., Marquez Avila H., Gulley J.M. A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 2008, 195:469-478.
26. Hanson K.L., Luciana M., Sullwold K. Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users. Drug Alcohol Depend. 2008, 96:99-110.
27. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+?) 3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci. 1999, 19:5096-5107.
28. Hesslinger B., Tebartz van Elst L., Thiel T., Haegele K., Henning J., Ebert D. Frontoorbital volume reductions in adult patients with attention deficit hyperactivity disorder. Neurosci. Lett. 2002, 328:319-321.
29. Hoffman W.F., Moore M., Templin R., McFarland B., Hitzemann R.J., Mitchell S.H. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl) 2006, 188:162-170.
30. Jager G., de Win M.M.L., Vervaeke H.K., Schilt T., Kahn R.S., van den Brink W., van Ree J.M., Ramsey N.F. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in prospective fMRI study. Psychopharmacology (Berl) 2007, 193:403-414.
31. Jones D.K., Symms M.R., Cereignani M., Howard R.J. The effect of filter size on VBM analyses of DT-MRI data. Neuroimage 2005, 26:546-554.
32. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 2005, 162:1403-1413.
33. Kim S.J., Lyoo I.K., Hwang J., Chung A., Hoon Sung Y., Kim J., Renshaw P.F. Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 2006, 9:221-228.
34. Koechlin E., Hyafil A. Anterior prefrontal function and the limits of human decision-making. Science 2007, 318:594-598.
35. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
36. Kringelbach M.L., Rolls E.T. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog. Neurobiol. 2004, 72:341-372.
37. Madras B.K., Miller G.M., Fischman A.J. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol. Psychiatry 2005, 57:1397-1409.
38. Martin G.W., Wilkinson D.A., Kapur B.M. Validation of self-reported cannabis use by urine analysis. Addict. Behav. 1988, 13:147-150.
39. Matochik J.A., London E.D., Eldreth D.A., Cadet J.L., Bolla K.I. Frontal cortical tissue composition in abstinent cocaine abusers: a magnetic resonance imaging study. Neuroimage 2003, 19:1095-1102.
40. Mechtcheriakov S., Brenneis C., Egger K., Koppelstaetter F., Schocke M., Marksteiner J. A widespread distinct pattern of cerebral atrophy in patients with alcohol addiction revealed by voxel-based morphometry. J. Neurol. Neurosurg. Psychiatry 2007, 78:610-614.
41. Melega W.P., Raleigh M.J., Stout D.B., Lacan G., Huang S.C., Phelps M.E. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 1997, 766:113-120.
42. Moeller F.G., Steinberg J.L., Lane S.D., Buzby M., Swann A.C., Hasan K.M., Kramer L.A., Narayana P.A. Diffusion tensor imaging in MDMA users and controls: association with decision making. Am. J. Drug Alcohol Abuse 2007, 33:765-767.
43. Ornstein T.J., Iddon J.L., Baldacchino A.M., Sahakian B.J., London M., Everitt B.J., Robbins T.W. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23:113-126.
44. Parrott A.C., Sisk E., Turner J.J.D. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend. 2000, 60:105-110.
45. Quednow B.B., Kühn K.U., Hoppe C., Westheide J., Maier W., Daum I., Wagner M. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharmacology (Berl) 2007, 189:517-530.
46. Quinton M.S., Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J. 2006, 8:337-347.
47. 123I]beta-CIT SPECT study-preliminary report. Psychopharmacology 2002, 159:335-340.
48. Reneman L., de Win M.M.L., van den Brink W., Booij J., den Heeten G.J. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Pharmacol. 2006, 20:164-175.
49. Ricaurte G.A., Martello A.L., Katz J.L., Martello M.B. Lasting effects of (+?)-3, 4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J. Pharmacol. Exp. Ther. 1992, 261:616-622.
50. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. (+?)3, 4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in non-human primates. JAMA 1998, 260:51-55.
51. Roesch M.R., Olson C.R. Neuronal activity related to reward value and motivation in primate frontal cortex. Science 2004, 304:307-310.
52. Rogers R.D., Everitt B.J., Baldacchino A., Blackshaw A.J., Swainson R., Wynne K., Hunter J., Carthy T., Booker E., London M., Deakin J.F.W., Sahakian B.J., Robbins T.W. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 1999, 20:322-339.
53. Rolls E.T. The functions of the orbitofrontal cortex. Brain Cogn. 2004, 55:11-29.
54. Rothe M., Pragst F., Spiegel K., Harrach T., Fischer K., Kunkel J. Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Sci. Int. 1997, 89:111-128.
55. Rueckert D., Sonoda L.I., Hayes C., Hill D.L.G., Leach M.O., Hawkes D.J. Non-rigid registration using free-form deformations: application to breast MR images. IEEE Trans. Med. Imaging 1999, 18:712-721.
56. Ryan L.J., Linder J.C., Marton M.E., Groves P.M. Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 1990, 518:67-77.
57. Salo R., Nordahl T.E., Natsuaki Y., Leamon M.H., Galloway G.P., Waters C., Moore C.D., Buonocore M.H. Attentional control and brain metabolite levels in methamphetamine abusers. Biol. Psychiatry 2007, 61:1272-1280.
58. Schilt T., de Win M.M.L., Koeter M., Jager G., Korf D., van den Brink W., Schmand B. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch. Gen. Psychiatry 2007, 64:728-736.
59. Schoenebaum G., Roesch M.R. Orbitofrontal cortex, associative learning, and expectancies. Neuron 2005, 47:633-636.
60. Schoenebaum G., Shaham Y. The role of orbitofrontal cortex in drug addiction: a review of preclinical studies. Biol. Psychiatry 2008, 63:256-262.
61. Schoenebaum G., Roesch M.R., Stalnaker T.A. Orbitofrontal cortex, decision-making and drug addiction. Trends Neurosci. 2006, 29:116-124.
62. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155.
63. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E.J., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., Niazy R.K., Saunders J., Vickers J., Zhang Y., De Stefano N., Brady J.M., Matthews P.M. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23:208-219.
64. Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E.J. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006, 31:1487-1505.
65. Taki Y., Kinomura S., Sato K., Goto R., Inoue K., Okada K., Ono S., Kawashima R., Fukuda H. Both global gray matter volume and regional gray matter volume negatively correlate with lifetime alcohol intake in non-alcohol-dependent Japanese men: a volumetric analysis and a voxel-based morphometry. Alcohol Clin. Exp. Res. 2006, 30:1045-1050.
66. Tanabe J., Tregellas J.R., Dalwani M., Thompson L., Owens E., Crowley T., Banich M. Medial orbitofrontal cortex grey matter is reduced in abstinent substance-dependent individuals. Biol. Psychiatry 2009, 62:160-164.
67. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee Y.L., Toga A.W., Ling W., London E.D. Structural abnormalities in the brains of human subjects who use methamphetamines. J. Neurosci. 2000, 24:6028-6036.
68. UNODC United Nations Office on Drug and Crime World drug Report, 2009. Available at Accessed October 8, 2009. http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf.
69. Valdes I.H., Steinberg J.L., Narayana P.A., Kramer L.A., Dougherty D.M., Swann A.C., Barratt E.S., Moeller F.G. Impulsivity and BOLD fMRI activation in MDMA users and healthy control subjects. Psychiatry Res. 2006, 147:239-242.
70. Yamamoto B.K., Moszcynska A., Gudelsky A.G. Amphetamine toxicities: classical and emerging mechanisms. Ann. N. Y. Acad. Sci. 2010, 1187:101-121.
71. Zolkowska D., Rothman R.B., Baumann M.H. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J. Pharmacol. Exp. Ther. 2006, 318:604-610.